Cargando…
Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer
The current standard of care for many patients with HER2-positive breast cancer is neoadjuvant chemotherapy in combination with anti-HER2 agents, based on HER2 amplification as detected by in situ hybridization (ISH) or protein immunohistochemistry (IHC). However, hematoxylin & eosin (H&E) t...
Autores principales: | Farahmand, Saman, Fernandez, Aileen I., Ahmed, Fahad Shabbir, Rimm, David L., Chuang, Jeffrey H., Reisenbichler, Emily, Zarringhalam, Kourosh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221954/ https://www.ncbi.nlm.nih.gov/pubmed/34493825 http://dx.doi.org/10.1038/s41379-021-00911-w |
Ejemplares similares
-
HEROHE Challenge: Predicting HER2 Status in Breast Cancer from Hematoxylin–Eosin Whole-Slide Imaging
por: Conde-Sousa, Eduardo, et al.
Publicado: (2022) -
Strategies for Enhancing the Multi-Stage Classification Performances of HER2 Breast Cancer from Hematoxylin and Eosin Images
por: Shovon, Md. Sakib Hossain, et al.
Publicado: (2022) -
A study to evaluate the efficacy of xylene-free hematoxylin and eosin staining procedure as compared to the conventional hematoxylin and eosin staining: An experimental study
por: Ankle, Madhuri R, et al.
Publicado: (2011) -
Evaluation of biosafe alternative to eosin in hematoxylin and eosin staining procedure: A comparative study
por: Pradeepthi, Katakam, et al.
Publicado: (2023) -
Comparison of Special Stains for Keratin with Routine Hematoxylin and Eosin Stain
por: Rao, Roopa S, et al.
Publicado: (2015)